Insmed (NASDAQ:INSM – Get Free Report) issued its earnings results on Thursday. The biopharmaceutical company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.08), FiscalAI reports. The company had revenue of $524.43 million during the quarter, compared to analysts’ expectations of $500.36 million. Insmed had a negative net margin of 76.94% and a negative return on equity of 123.94%. The firm’s quarterly revenue was up 268.4% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($1.75) earnings per share.
Here are the key takeaways from Insmed’s conference call:
- BRINSUPRI’s launch continues to materially outperform expectations: Third-quarter revenue reached $400.1 million, up 29% sequentially, and the product surpassed $1 billion in its first four full quarters. Insmed raised 2026 BRINSUPRI guidance to $1.35 billion-$1.4 billion.
- ARIKAYCE also delivered steady growth and faces a major potential market expansion. Third-quarter revenue rose 9% year over year to $124.4 million, prompting higher 2026 guidance of $460 million-$470 million; FDA priority review for a broader MAC lung disease label has a January 28, 2027 action date.
- Insmed expects to reach cash-flow positivity in 2027. The company ended the quarter with approximately $1.1 billion in cash, while management said BRINSUPRI’s growth should improve operating leverage even as investments continue across the pipeline.
- The long-term pipeline remains a significant growth driver, led by TPIP. TPIP’s four Phase 3 studies are advancing, with the PH-ILD trial more than 35% enrolled and ahead of schedule; management estimates more than $6 billion in peak sales potential, although approvals and clinical outcomes remain uncertain.
- Insmed is pursuing a large but still unquantified expansion of BRINSUPRI’s opportunity in COPD and asthma patients with undiagnosed comorbid bronchiectasis. AI diagnostic tools, imaging studies, physician education and other initiatives are underway, with initial findings expected around mid-2027; management characterized the opportunity as substantial but acknowledged that adoption will take time.
Insmed Stock Performance
INSM stock traded up $2.04 during midday trading on Friday, reaching $113.63. The company had a trading volume of 1,806,674 shares, compared to its average volume of 2,976,641. Insmed has a fifty-two week low of $90.39 and a fifty-two week high of $212.75. The company has a quick ratio of 3.40, a current ratio of 3.72 and a debt-to-equity ratio of 0.74. The stock has a 50 day moving average price of $112.91 and a 200 day moving average price of $125.96. The firm has a market capitalization of $24.81 billion, a PE ratio of -27.60 and a beta of 0.83.
Insmed News Summary
Here are the key news stories impacting Insmed this week:
- Positive Sentiment: BRINSUPRI sales exceeded expectations. Third-quarter BRINSUPRI revenue reached $400.1 million, up 29% sequentially. Management said the U.S. launch continues to exceed expectations, supporting optimism that the drug can become a major growth driver. Insmed Soars on BRINSUPRI Revenue
- Positive Sentiment: Insmed raised its full-year outlook. The company increased 2026 BRINSUPRI revenue guidance to $1.35 billion-$1.40 billion and ARIKAYCE guidance to $460 million-$470 million. ARIKAYCE third-quarter revenue was $124.4 million, up 9% from a year earlier. Insmed Third-Quarter Financial Results
- Positive Sentiment: Revenue significantly surpassed estimates. Total third-quarter revenue was $524.4 million, up 268.4% year over year and above analyst expectations of approximately $500.4 million. The company also launched BRINSUPRI in Japan, expanding its commercial opportunity. Insmed Third-Quarter Earnings Results
- Positive Sentiment: Trading activity reflected bullish interest. Investors purchased 7,706 call options, more than double the typical daily volume, indicating increased speculative interest in further stock gains, although options activity is not a fundamental indicator.
- Neutral Sentiment: The quarterly loss narrowed substantially. Insmed reported a loss of $0.46 per share versus a $1.75 loss a year earlier, while the company remains unprofitable as it invests behind its commercial launches.
- Negative Sentiment: Adjusted earnings missed expectations. The $0.46 per-share loss was wider than consensus estimates, which were reported between $0.34 and $0.38 per share. The miss could temper enthusiasm despite the stronger revenue and outlook.
Wall Street Analysts Forecast Growth
Several analysts have recently issued reports on the stock. Stifel Nicolaus set a $195.00 price target on shares of Insmed in a research report on Thursday. JPMorgan Chase & Co. cut their price target on Insmed from $179.00 to $175.00 and set an “overweight” rating on the stock in a research report on Monday, August 10th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $235.00 target price on shares of Insmed in a report on Tuesday, July 28th. BMO Capital Markets restated an “outperform” rating on shares of Insmed in a research report on Tuesday, October 6th. Finally, Barclays lowered their price objective on Insmed from $237.00 to $207.00 and set an “overweight” rating on the stock in a report on Wednesday, September 30th. One analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $196.70.
Read Our Latest Research Report on INSM
Insider Buying and Selling
In related news, COO Roger Adsett sold 239,850 shares of the firm’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $133.27, for a total value of $31,964,809.50. Following the sale, the chief operating officer directly owned 98,744 shares in the company, valued at $13,159,612.88. This trade represents a 70.84% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director David Brennan sold 25,000 shares of the stock in a transaction on Wednesday, September 9th. The shares were sold at an average price of $124.00, for a total value of $3,100,000.00. Following the transaction, the director directly owned 39,238 shares of the company’s stock, valued at approximately $4,865,512. The trade was a 38.92% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders own 2.10% of the company’s stock.
Insmed Company Profile
Insmed Incorporated is a global biopharmaceutical company focused on developing and commercializing therapies for serious and rare diseases. The company concentrates on conditions with significant unmet medical needs, particularly in pulmonary and infectious diseases.
Insmed’s lead commercial product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled antibacterial therapy used in the United States for adults with refractory Mycobacterium avium complex lung disease as part of a combination antibacterial regimen.
See Also
- Five stocks we like better than Insmed
- FTC Puts A Wrinkle In the Cintas and UniFirst Merger
- Breaching the Valuation: The Real Reason Fortinet Dropped
- Microsoft Earnings Expose a Growing Divide in the Magnificent 7 AI Trade
- Silicon Shock: Intel’s 25% Valuation Reset
Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.
